5-Piperidino-7--s-triazolo<1,5-a>pyrimidin | 100557-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 5-Piperidino-7--s-triazolo<1,5-a>pyrimidin
• 英文别名: 5-piperidino-7--s-triazolo<1,5-a>pyrimidine；5-piperidino-7-(N-(n-hexyl)-N-(β-hydroxyethyl)-amino)-s-triazolo[1,5-a]pyrimidine；2-[Hexyl-(5-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)amino]ethanol
• CAS: 100557-07-1
• 化学式: C₁₈H₃₀N₆O
• 分子量: 346.476
• InChiKey: CAUSJFJJYRCTPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Treating extrapyramidal syndrome using trapidil
  申请人：Sinopia Biosciences, Inc.

  公开号：US10350212B2

  公开（公告）日：2019-07-16

  Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

  本文公开了一些方法、药物组合或试剂盒，用于预防或治疗锥体外系综合征，例如运动障碍、肌张力障碍、肌张力障碍或药物诱发的帕金森氏症，服用治疗有效量的曲吡地尔、其衍生物、代谢物、原药、类似物或其药学上可接受的盐。
• TREATING EXTRAPYRAMIDAL SYNDROME USING TRAPIDIL
  申请人：Sinopia Biosciences, Inc.

  公开号：US20190328741A1

  公开（公告）日：2019-10-31

  Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
• TREATING COGNITIVE DISORDERS USING TRAPIDIL
  申请人：Sinopia Biosciences, Inc.

  公开号：US20220378794A1

  公开（公告）日：2022-12-01

  Disclosed herein are methods, pharmaceutical combinations, and dosage combinations for the prevention or treatment of cognitive disorders with the administration of a therapeutic effective amount of trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof. In some embodiments, the trapidil, derivative, metabolite, prodrug, analog, or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent, such as an antidepressant agent, an antipsychotic agent, an anxiolytic agent, a dopamine precursor, or a dopamine agonist.
• US6369065B1
  申请人：——

  公开号：US6369065B1

  公开（公告）日：2002-04-09
• [EN] TREATING COGNITIVE DISORDERS USING TRAPIDIL<br/>[FR] TRAITEMENT DE TROUBLES COGNITIFS À L'AIDE DE TRAPIDIL
  申请人：SINOPIA BIOSCIENCES INC

  公开号：WO2021113266A1

  公开（公告）日：2021-06-10

  Disclosed herein are methods, pharmaceutical combinations, and dosage combinations for the prevention or treatment of cognitive disorders with the administration of a therapeutic effective amount of trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof. In some embodiments, the trapidil, derivative, metabolite, prodrug, analog, or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent, such as an antidepressant agent, an antipsychotic agent, an anxiolytic agent, a dopamine precursor, or a dopamine agonist.